Effects of anticholinergic drugs on cognitive function in older Australians: Results from the AIBL study

Dementia and Geriatric Cognitive Disorders

Volumn 31, Issue 3, 2011, Pages 173-178

  Sittironnarit, Gobhathai ^a   Ames, David ^b,e   Bush, Ashley I ^c,d   Faux, Noel ^c   Flicker, Leon ^i,j   Foster, Jonathan ^k,l   Hilmer, Sarah ^m   Lautenschlager, Nicola T ^e,i,j   Maruff, Paul ^e,f   Masters, Colin L ^c,d,e   Martins, Ralph N ^k,l   Rowe, Christopher ^g   Szoeke, Cassandra ^b,h   Ellis, Kathryn A ^b,c,e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d Department of Pathology ^*  (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f CogState Ltd ^*  (Australia)

^g AUSTIN HEALTH   (Australia)

^h CSIRO   (Australia)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^l EDITH COWAN UNIVERSITY   (Australia)

^m UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Acetylcholine; Anticholinergic scale; Cognition; Elderly; Medications; Memory

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ANXIETY; ARTICLE; AUSTRALIA; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRUG EXPOSURE; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RESPONSE TIME; SIDE EFFECT; VERBAL MEMORY;

AGED; AGING; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHOLINERGIC ANTAGONISTS; COGNITION; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYPHARMACY; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 79952332489     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000325171     Document Type: Article

References (18)

1. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG: Antimuscarinic drugs for overactive bladder in older patients. J Am Geriatr Soc 2005; 53: 2195-2001.
2. Ellis JR, Ellis KA, Bartholomeusz CF, Harrison BJ, Wesnes KA, Erskine FF, Vitetta L, Nathan PJ: Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol 2006; 9: 175-189. (Pubitemid 43255831)
3. Wesnes KA, Simpson PM, Kidd AG: An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s.c. Hum Psychopharmacol 1988; 3: 27-41.
4. Auld DS, Kornecook TJ, Bastianetto S, Quirion R: Alzheimers disease and the basal forebrain cholinergic system: relations to betaamyloid peptides, cognition, and treatment strategies. Progr Neurobiol 2002; 68: 209-245. (Pubitemid 35346805)
5. Michel NL, Molimard M, Dartigues JF, Fabrigoule C, Reglat AF: Drugs with anticholinergic properties and cognitive performance in elderly: results from the PAQUID study. Br J Clin Pharmacol 2004; 59: 143-151. (Pubitemid 40208849)
6. Han L, Agostini JV, Allore HG: Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56: 2203-2210.
7. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K: Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332: 455-459.
8. Flicker C, Ferris SH, Serby M: Hypersensitivity to scopolamine in the elderly. Psychopharmacology 1992; 107: 437-441.
9. Bottiggi KA, Salazar JC, Yu L, Caban-Holt AM, Ryan M, Mendiondo MS, Schmitt FA: Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006; 14: 980-984. (Pubitemid 44706417)
10. Gallagher P, O'Mahony D: Inappropriate prescribing in older people. Clin Gerontol 2008; 18: 65-76.
11. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D, AIBL Research Group: The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1,112 individuals recruited for a longitudinal study of Alzheimers disease. Int Psychogeriatr 2009; 21: 672-687.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E: Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
13. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308. (Pubitemid 29120227)
14. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment- beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246. (Pubitemid 39222993)
15. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, Kirshner MA, Sorisio DA, Bies RR, Gharabawi G: Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56: 1333-1341.
16. Rudolph JL, Salow MJ, Angelini MC, Mc- Glinchey RE: The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2009; 168: 508-513. (Pubitemid 351547214)
17. Gnjidic D, Cumming RG, Le Couteur DG, Handelsman DJ, Naganathan V, Abernethy DR, Hilmer SN: Drug Burden Index and physical function in older Australian men. Br J Clin Pharmaco 2009; 68: 97-105.
18. Cancelli I, Gigli GL, Piani A, Zanchettin B, Janes F, Rinaldi A, Valente M: Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people. J Clin Psychopharmacol 2008;28:654-659.